Use of aerosolized tissue plasminogen activator in the treatment of plastic bronchitis

Area of Science:

• Pediatric critical care medicine
• Cardiology
• Pulmonology

Background:

• Plastic bronchitis is a rare but serious condition characterized by the formation of mucus casts in the bronchial tree, leading to airway obstruction and impaired gas exchange.
• Patients with Fontan circulation are at increased risk for developing plastic bronchitis, posing significant management challenges.
• Limited effective treatment options exist for plastic bronchitis, often necessitating repeated airway interventions.

Observation:

• A 13-year-old patient with a history of corrected congenital heart disease presented with severe respiratory distress due to extensive mucus plugging from plastic bronchitis.
• Manual removal of bronchial casts provided only temporary relief, with rapid reaccumulation observed.
• A novel treatment regimen involving aerosolized tissue plasminogen activator (t-PA) was initiated to dissolve existing casts and prevent new formations.

Findings:

• Nebulized t-PA demonstrated success in breaking down bronchial casts and preventing their recurrence over a 17-day treatment period.
• The pediatric patient showed significant improvement in respiratory status and was discharged without evidence of bronchial casts.
• This case adds to the growing evidence supporting the safety and efficacy of aerosolized t-PA for plastic bronchitis.

Implications:

• Aerosolized t-PA represents a potentially valuable therapeutic option for managing plastic bronchitis, particularly in high-risk pediatric populations like those with Fontan procedures.
• Further research is warranted to establish optimal dosing, treatment duration, and long-term outcomes for nebulized t-PA in plastic bronchitis.
• This treatment approach may improve oxygen exchange and quality of life for patients suffering from this debilitating condition.